Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaishi Tuire granules (CSTRG) is a traditional Chinese patent medicine widely used in China for the treatment of respiratory infections, particularly influenza. It is a multi-herb formulation composed of ten traditional Chinese medicinal herbs, including *Lonicera japonica* Thunb, *Rheum officinale*, *Bupleuri Radix*, *Isatis indigotica*, *Forsythia suspensa*, *Artemisia annua*, *Anemarrhena asphodeloides*, *Taraxacum* (Dandelion), *Scutellaria baicalensis*, and Gypsum Fibrosum. CSTRG exerts its therapeutic effects primarily through anti-inflammatory and immunomodulatory mechanisms, specifically by inhibiting the expression of pro-inflammatory cytokines such as TNF-alpha and IL-6 via the modulation of the TRAF6/MAPK14 signaling pathway. It is clinically evaluated in Phase 4 trials for the treatment of adult influenza, demonstrating efficacy in fever resolution and symptom improvement comparable to oseltamivir.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaishi Tuire granules.